Jennifer Below, Ph.D.
- Professor of Medicine
- Director, Vanderbilt Genetics Institute (VGI)
Jennifer Below, Ph.D.
- Professor of Medicine
- Director, Vanderbilt Genetics Institute (VGI)
jennifer.e.below@vanderbilt.edu
Research Program
Research Description
Eden Biltibo, M.D., M.S.C.I.
- Assistant Professor of Medicine
Eden Biltibo, M.D., M.S.C.I.
- Assistant Professor of Medicine
eden.a.biltibo@vumc.org
Research Program
Research Description
This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach, clinical management of comorbidities (CMC) focuses on managing multiple diseases, other than cancer, such as heart or lung diseases through physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education. Giving SPC, CMC, or a combination of both may work better in improving quality of life and survival after a donor stem cell transplant compared to standard of care in patients with blood diseases.
Lauren Woodard, PhD
- Assistant Professor of Nephrology
Lauren Woodard, PhD
- Assistant Professor of Nephrology
lauren.woodard@vumc.org
Research Program
Research Description
This study is being done to find out if tucatinib with other cancer drugs works better than
standard of care to treat participants with HER2 positive colorectal cancer. This study will
also test what side effects happen when participants take this combination of drugs. A side
effect is anything a drug does to the body besides treating your disease.
Participants in this study have colorectal cancer that has spread through the body
(metastatic) and/or cannot be removed with surgery (unresectable).
Participants will be assigned randomly to the tucatinib group or standard of care group. The
tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group
will get either:
- mFOLFOX6 alone,
- mFOLFOX6 with bevacizumab, or
- mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs
given in this study are used to treat this type of cancer.
